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Abstract 
 
Aims: The treatment of prostate cancer has evolved markedly over the last forty years, including 
radiotherapy, notably with escalated dose and targeting. However, the optimal treatment for 
localised disease has not been established in comparative randomised trials. We aim to describe 
the history of prostate radiotherapy trials, including their QA processes, and compare these with 
the ProtecT trial. 
Materials and methods: The UK ProtecT trial compares radiotherapy, surgery and active 
monitoring for localised prostate cancer and will report this year following recruitment between 
1999-2009. The embedded QA programme consisted of on-site machine dosimetry at the nine 
centres, a retrospective review of outlining and adherence to dose constraints based on the trial 
protocol in 54 patients (randomly selected, around 10% of total randomised to radiotherapy). 
Processes and results were compared with prostate radiotherapy trials of a comparable era. 
Results: There has been an increasingly sophisticated QA programme in UK prostate 
radiotherapy trials over the last 15 years reflecting dose escalation and treatment complexity. In 
ProtecT, machine dosimetry results were comparable between trial centres and with the RT01 trial. 
The outlining review showed that the majority of deviations were clinically acceptable although 
three (1.4%) may have been of clinical significance and were related to outlining of the prostate. 
Seminal vesicle outlining varied, possibly due to several prostate trials running concurrently with 
different protocols. Adherence to dose constraints in ProtecT was considered acceptable with 80% 
of patients having two or less deviations and PTV coverage was excellent. 
Conclusion: The ProtecT QA results were satisfactory and comparable to trials of its era. Future 
trials should aim to standardise treatment protocols and QA programmes where possible to reduce 
complexities for centres involved in multiple trials. 
 
 
Research Highlights  
 The optimal treatment for localised prostate cancer has not been established by 
randomised evidence  Radiotherapy can be curative for localised disease  Trial QA is necessary with increasing radiotherapy dose and complexity  ProtecT compares active monitoring, radiotherapy and surgery and reports this year  The ProtecT QA programme was comparable to other UK trials of its era with satisfactory 
results 
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Introduction 
 
Later on this year, the first outcome data from the UK ProtecT trial will be reported. In this 
landmark NIHR-funded trial, men with localised prostate cancer were randomised to radical 
prostatectomy, external beam radiotherapy, or active monitoring [1]. Whether or not there are 
differences in outcomes between these three approaches, there will undoubtedly be an appraisal 
of the trial’s treatment technique in the light of today’s technology, the use of dose escalation in 
‘conventional’ 2 Gy fractions and the quality assurance data. This is inevitable, given that the 
ProtecT trial is unique in comparing three prostate treatment modalities, probably was only 
achievable when it was done and in the UK – and so will never be repeated. There have been a 
several other landmark trials in the UK of radiotherapy for prostate cancer, including the Medical 
Research Council (MRC) RT01 and PR07 trials, the Cancer Research UK/NIHR Cancer Research 
Network CHHIP trial, and exploratory data from the MRC STAMPEDE trial [2-5]. This article aims 
to put these radiotherapy trials into their historical context as a backdrop for what will be an historic 
occasion when the first results of the ProtecT trial are unveiled this year. 
 
 
Radiotherapy for prostate cancer; technology shifts the 
goalposts 
 
The first descriptions of radiotherapy for prostate cancer come from the early 1900s, when reports 
of radium needle insertions were published in the Journal of the American Medical Association [6]. 
The advent of external beam radiotherapy during the course of the century led to more patients 
being treated, but a paucity of evidence. Notable from the era in the 1970’s and early 1980’s were 
the Stanford case series of Bagshaw, which laid the foundations of clinical practice [7]. At that time, 
conventional radiotherapy planning involved a planning cystogram, and the manual definition of 
radiotherapy fields based - ultimately - on the physician’s opinion. The advent of CT planning in the 
late 1980’s radically changed practice, the initial hope being that radiotherapy fields could be made 
smaller, because the tumour definition was more accurate, and so more normal tissue would be 
spared. In fact, the hope was based on a false premise, though the reasoning was correct. Tumour 
definition was much more precise, but in turn radiotherapy fields often became larger, as it was 
evident, in retrospect, that geographical miss had been more common than was previously 
supposed [8]. 
 
Using CT planning, it was also possible to accurately define the extent of rectum included in a high 
dose volume, even though there was no obvious consensus as to how much rectal irradiation was 
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‘acceptable’. The new level of accuracy, coupled with isocentric planning and delivery on linear 
accelerators rather than on cobalt, also permitted another development - conformal radiotherapy. 
In its early days, this was achieved by the manufacture of customised lead blocks, which were 
mounted on a tray placed on the linear accelerator head. It was presumed that this would, by 
reducing the volume of normal tissue irradiated, also reduce radiotherapy side effects, and this was 
proven in a landmark publication of  the first randomised trial comparing conformal and 
conventional radiotherapy for pelvic tumours [9].  
 
Even in the early days of conformal radiotherapy, another goal was envisaged - that of dose 
escalation, based on the philosophy that, if a rate of 5% of grade 3-4 late toxicity was “acceptable”, 
and if conformal radiotherapy reduced this rate, it would permit dose escalation, hopefully with 
improved tumour control, titrated against this “acceptable” level of toxicity. Several randomised 
trials of dose escalation for prostate cancer were opened in the 1990’s, following pilot studies 
which suggested that this approach was safe, and these trials have now all reported outcome data 
[2,10-13]. Though dose-escalation is now routine practice, it was not state of the art in external 
beam radiotherapy for prostate cancer at the time when the UK ProtecT study was designed in the 
late 1990’s. Importantly, though several clinical centres had the capacity for conformal 
radiotherapy, it was by no means uniformly available across the UK, and even CT planning was 
not universal at that time.  
 
In the ProtecT trial, patients with clinically organ-confined prostate cancer were to be randomised 
to radical prostatectomy, radical external beam radiotherapy, or active monitoring. The problem for 
the designers of ProtecT in the late 1990s was how to make the radiotherapy technique as ‘future-
proof’ as possible, against a backdrop of limited or non-existent evidence of long term efficacy. Too 
conservative, and in the event of radiotherapy turning out to be less effective, the trial would be 
criticised for under-treating patients. Too aggressive, and it would be criticised for over-treating 
patients. Another factor in the UK was the increasing use of neo-adjuvant hormone therapy in 
combination with radiotherapy and whether this was also to be included in the ProtecT trial 
although this was not standard practice in the USA. Other contrasts existed between the UK and 
the USA in terms of dose escalation; in the US, the dose per fraction was limited to 1.8 Gy and the 
total dose was being escalated to 78 or 80 Gy [14], whilst in the UK, the dose per fraction was 2 Gy 
and the total dose was limited to 74 Gy. The latter technique was employed in the MRC’s RT01 
trial [2], which recruited between 1998-2001 and randomised patients to a ‘standard’ dose of 64 Gy 
in 32 fractions, versus an escalated dose of 74 Gy in 37 fractions. 
 
In the event, the technique chosen for ProtecT was similar to that used for RT01, in that it 
employed (a) neo-adjuvant hormone therapy, and (b) dose escalated radiotherapy to a total of 74 
Gy in 37 fractions. There were, however, differences between the two trials; although the treatment 
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was given in two phases, in RT01 the phase II dose was 10 Gy, whereas in ProtecT it was 18 Gy. 
ProtecT also had organ at risk dose constraints pre-specified, unlike in RT01. 
 
The ProtecT trial recruited patients from late 1999 to early 2009, a period when technical 
developments in radiotherapy have continued apace. Firstly, came the development of portal 
imaging - another technology that was far from universal in the UK at the ProtecT trial outset. 
Then, the first reports of Intensity Modulated Radiotherapy (IMRT) for prostate cancer, and 
subsequently the use of Image Guided Radiotherapy (IGRT) led to a growing pressure to use 
these techniques routinely [15,16]. Indeed, the current European Guidelines state that the use of 
IMRT for prostate cancer radiotherapy should now be standard [17]. Conceptually, the argument 
for IMRT is compelling, but does that weaken the conclusions from trials which came too early to 
use it? It could be argued that long term radiotherapy toxicity in trials such as RT01 and ProtecT 
might have been lessened through the use of IMRT, but in a comparative setting with other 
modalities, similar arguments could also be made about the evolution of open to robotic 
prostatectomy. 
 
 
Evidence versus belief; does definitive local therapy 
cure prostate cancer? 
 
Internationally, the immense uncertainties around treatment of localised  prostate cancer were the 
context for the first randomised trials in which one arm was - essentially - no treatment. These 
were studies of radical prostatectomy versus ‘watchful waiting’. The latter is a strategy in which 
treatment is explicitly avoided unless given for symptoms - so by implication it is palliative only. 
Two such trials have reported mature results: the Scandinavian SPCG-4 and the US PIVOT trials. 
 
In SPCG-4, men were diagnosed through clinically apparent, as opposed to PSA screen-detected 
disease, and were, therefore, often symptomatic. In that trial, 695 men were randomised to radical 
prostatectomy (n = 347) or watchful waiting (n = 348) with a median follow-up of 12 years. Overall, 
there was a significant disease-specific survival advantage for men treated with surgery, but a 
more recent analysis has indicated that this benefit was greatest for men either 65 years old or 
younger or with intermediate disease risk at diagnosis [18]. In the PIVOT trial, radical 
prostatectomy (n = 367) was compared with watchful waiting (n = 364) with a primary outcome of 
all-cause mortality and secondary outcomes of prostate specific mortality, metastases and 
symptoms in a largely screen-detected population. There was no difference in overall or disease-
6 
 
specific survival at a median of 10 years, but in a sub-group analysis men with a PSA of 10 ng/ml 
and above or intermediate risk disease had a survival advantage with surgery [19]. 
 
These two trials do, at least, provide some degree of proof of concept that definitive therapy might 
indeed cure, or at any rate prolong the survival of, some men with prostate cancer. However, both 
were surgical trials; there are no large trials comparing radical radiotherapy to watchful waiting or 
surgery for localised disease. Radiotherapy after surgery also conferred a clinical progression-free 
survival advantage in the EORTC 22911 trial over no additional treatment in men younger than 70 
years and those with positive surgical margins with pathological T3 disease [20]. 
 
In locally advanced disease there are more data pertaining to radiotherapy. In the influential 
EORTC 22861 trial, men with predominantly locally advanced disease were randomised to 
radiotherapy, or to radiotherapy and hormone therapy [21]. Overall survival was substantially better 
in men treated additionally with hormone therapy, but what was the contribution of each? The 
SPCG-7 and intergroup MRC PR3/PR07 studies randomised men with predominantly localised 
(SPCG) or predominantly locally advanced (MRC) disease to hormone therapy alone, or to 
hormone therapy plus radiotherapy. In both trials, men who received radiotherapy had significantly 
better overall survival than men treated with hormone therapy alone [3,22]. Thus, at least in the 
context of locally advanced disease, radical radiotherapy prolongs survival and conceivably might 
cure some men. ProtecT is, however, the only prostate cancer trial in the modern era which 
compares radiotherapy, surgery and active monitoring - the latter permitting deferred radical 
therapy, and is almost the only trial comparing surgery and radiotherapy. The two previous 
randomised trials of surgery versus radiotherapy in localised or locally advanced disease failed to 
answer the question as they were too small, and the radiotherapy techniques would be considered 
suboptimal today [23,24], whilst a further Swedish trial of radiotherapy versus watchful waiting only 
published quality of life outcomes [25].  
 
 
The impact of dose escalation and the introduction of 
quality assurance into UK clinical trials 
 
With the advent of dose escalation came an absolute requirement for ensuring that radiotherapy 
was meticulously planned according to pre-defined criteria and consistently delivered. This might 
be taken for granted now, but it was far from self-evident at the time when the RT01 and ProtecT 
trials were in design. Across the UK there was wide variation in institutional dose and fractionation 
[26,27]; there were no standard criteria defining prostate volumes, treatment margins, or the 
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sparing of critical normal tissues. Formal quality assurance programmes had been introduced into 
several of the randomised trials of dose escalation worldwide, but in the UK, the RT01 trial was the 
first of its kind that had an integrated, formal process of quality assurance [28]. In that trial, prostate 
volumes were pre-defined (Table 1), and planning margins were similarly defined after categorising 
patients according to their risk of seminal vesicles involvement, using an algorithm developed by 
the RTOG [29]. In the ProtecT study, a similar approach was adopted (Table 1) but with specified 
rectal and bladder dose constraints.  
 
 
A quality assurance programme with interlinked components was established in both ProtecT and 
RT01 trials. An early process in both trials was that all clinical centres were visited, and machine 
quality measured using phantom and other dosimetry [30]. No significant adverse findings were 
reported from these assessments in the RT01 study (mean dose difference -2%) [31] or the 
ProtecT study where the mean error in prediction from planned ranged from -4.4% to 0.2% across 
nine centres (Figure 1).  
 
In the RT01 study, an outlining exercise was performed by each centre with three practice cases, 
and the results of patient outlining were assessed both prospectively and retrospectively [32]. In 
the ProtecT study, recruitment started in three pilot centres in 1999 and increased to nine centres 
between 2002 to 20004. Consequently, as outlining exercises had already been completed by all 
but one study centre for either or both of the RT01 and CHHIP studies (which recruited between 
2002-2006), the focus of the on-trial outlining was through discussions of issues at ProtecT 
radiotherapy meetings with clinical centres. Subsequently, outlining was retrospectively reviewed 
by two radiotherapists (JNS and MDM). Three patients from the ‘low' and three from the 'moderate' 
risk group were randomly selected for each centre to represent a total of around 10% of patients 
randomised to radiotherapy (n = 545). Their CT and outlining data were visualised using the CERR 
(Computational Environment for Radiotherapy Research) software [33].   
 
Outlining was assessed against criteria in the ProtecT protocol. Outlines were classified according 
to whether they were satisfactory, "acceptable" (a deviation from the protocol, but acceptable 
clinical practice), or "unacceptable" (a protocol deviation with potential clinical consequences) and 
the results are summarised in Table 2. The PTV margins has no errors in outlining in the 108 
cases reviewed (two volumes/case). There were some variations from the protocol; however, only 
three (1.4%) were assessed as potentially being of clinical significance. These were all related to 
poor outlining of the prostate, possibly due to insufficient radiological anatomy knowledge or 
drawing target volumes as this was published in the mid-1990s and may have affected the pilot 
cases. The majority (16/23, 70%) of acceptable protocol variations were related to incorrect 
definition of the seminal vesicles and the majority of these (10/16, 63%) were in the definition of the 
8 
 
base of the seminal vesicles. We hypothesise that this relates to the concurrent recruitment to the 
RT01, CHHiP and ProtecT trials in centres as each trial had different definitions of the volume of 
seminal vesicles to be included in the base. This issue was not highlighted to clinical investigators 
at that time. Two examples of protocol violations in outlining are shown in Figure 2. 
 
In the RT01 study, although a prospective outlining exercise was performed, the first of its kind in a 
UK clinical trial [32], there was no possibility for assessment of adherence to pre-specified dose 
constraints in organs at risk. In the ProtecT study, adherence to 13 dose constraints, including the 
bladder (2) and rectum (5), the main organ at risk for treatment toxicity, were assessed by an 
independent radiotherapy physicist in the same cases selected for outline review, and the results 
are summarised in Figure 3. Many deviations were driven by clinical necessity, e.g. an 
unfavourable anatomy. Around 80% of the plans had two or fewer deviations so this was judged to 
show good overall adherence to the trial protocol. PTV1 coverage was fully met for 89% (46) of 
plans, with a further three between 95.8% and 98.0% and in the remaining three the dose was 
reduced probably for clinical reasons. Similar results were obtained for PTV2. 
 
The quality of radiotherapy planning and delivery was judged to be satisfactory in both RT01 and 
ProtecT trials. Deviation from the protocol has the potential to confound the study question and so 
quality assurance is, therefore, essential when comparing different treatments and trials. Our 
analysis of a subset of the radiotherapy plans demonstrates good understanding and adherence to 
the ProtecT protocol. Since then, pre-specified QA has become a requisite component, and of 
recent UK prostate trials, the most detailed programme is in the CHHIP study with single phase 
forward planned three-field IMRT [4].  
 
An outside observer might reasonably (though provocatively) ask; what has QA achieved in this 
setting? After all, some notable trials identified benefits for radiotherapy (RT) with QA features of 
their era (e.g. EORTC 2291 or EORTC 22863) sometimes without pre-specified constraints to 
organs at risk or with outlining reviews conducted retrospectively [2, 20,34]. The answer is twofold. 
Firstly, a common feature of these studies is that they were variations on a theme of "RT versus no 
RT"; modern radiotherapy trials either compare radiotherapy with another equivalent modality 
(ProtecT), or different techniques, doses, or schedules (e.g. RT01 and CHHIP) or the non-
randomised comparisons recently published from the STAMPEDE trial [35]. As the trend moves 
inexorably towards higher total dose equivalents, and fewer fractions [4], the desirability of highest 
quality treatment delivery becomes an absolute imperative - with much to lose in terms of adverse 
effects for patients otherwise.  
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The worldwide perspective and QA implementation in 
future trials  
 
Worldwide support for QA within radiotherapy trials has differed considerably. The US, via the 
Radiation Therapy Oncology Group (RTOG), has, with central funding, had formal QA programmes 
since the 1970’s for clinical trials employing radiotherapy with detailed credentialing for trial centres 
for IMRT trials [36]. Funding from RTOG has allowed on-trial review and analysis of trial outcomes 
against levels of protocol adherence which is currently beyond our scope in the UK. The EORTC 
Radiotherapy Group has also had a comprehensive QA programme since the 1980’s with 
centralised support and infrastructure for radiotherapy trials [37]. In due course it might be possible 
to analyse treatment failures in relation to the quality of treatment delivery, and ProtecT could be 
an exemplar when outcome data are available.  
 
A second key benefit of retrospective analysis of trial QA is learning for the future. It is now clear 
that groups setting up multiple trials in the same tumour site should aim to minimise differences in 
radiotherapy techniques between the trials. This has been an ongoing effort within the UK’s NCRI 
RadioTherapy Trials Quality Assurance group with notable successes across trials from different 
trial groups in rectal, oesophageal and pancreatic cancer trials [38]. However, there are still 
exceptions especially with large international collaborative trials which have detiailed QA 
programmes but they are not standardised with other trials within a country (e.g. PACE [39]:).  
 
 
Future Prospects - ProtecT and its impact 
 
An inherent feature of any technology-dependent study is that its technique will become obsolete. 
That will happen for today's sophisticated studies of IMRT and IGRT as surely as it did for 
conventional isocentrically planned radiotherapy. There is no doubt that, were trials such as 
ProtecT to be launched today, the QA programme would look very different to the way in which it 
was actually done. Will this impact on the interpretation of the ProtecT results, when they are finally 
released? It is essential that the standards of treatment delivery, whether surgery, radiotherapy (or 
indeed, active monitoring) are presented clearly and judged by the standards of their time. Against 
those standards it would seem that the radiotherapy delivery in trials such as ProtecT and RT01 
was, at the very least, satisfactory, and will not be a confounding factor when comparisons are 
made between the three ProtecT treatments for clinical and patient-reported outcomes. How those 
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findings are then related to modern techniques, or to other modalities such as focal therapy, SBRT, 
or brachytherapy, is a matter for future discussion, but those discussions will undoubtedly be better 
informed by quality assurance having been embedded in the ProtecT trial. 
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April 2012. 
Radiotherapy and medical physics: Helen Appleby, Dominic Ash, Dean Aston, Steven Bolton, 
Graham Chalmers, John Conway, Nick Early, Tony Geater, Lynda Goddall, Claire Heymann, 
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Histopathologists: Selina Bhattarai, Neeta Deshmukh, John Dormer, Malee Fernando, John 
Goepel, David Griffiths, Ken Grigor, Nick Mayer, Jon Oxley, Mary Robinson, Murali Varma, Anne 
Warren. 
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Table 1: Target volumes, treatment margins and dose constraints in the RT01 and ProtecT 
protocols 
 
 
Parameter RT01 (74 Gy arm) ProtecT 
Risk category Roach formula (Low & 
Moderate risk groups) 
Roach formula (Low & Moderate risk groups) 
Phase I CTV Prostate and base SV + 
0.5 mm (L) or SV (M) 
Prostate & base SV (L) or SV (M),  
Constraint: no margin beyond organ 
Phase I PTV CTV1 + 5-10 mm CTV1 + 10 mm 
Phase II CTV Prostate Prostate, Constraint: no margin beyond organ 
Phase II PTV As per CTV CTV2 + 5 mm 
Phase I dose and fractionation 64 Gy in 32# 56 Gy in 28# (PTV1 V95%, 53.2Gy) 
Phase II dose and fractionation 10 Gy in 5# 18 Gy in 9# (PTV2 V95%, 17.1Gy) 
Summed dose constraints  
 
Unique gantry angles  3 or 4 
  ICRU max D1.8cc ≤105% (77.7 Gy) 
Bladder Not to exceed prescribed 
dose to isocentre V74Gy <25% 
  V67Gy <50% 
Rectum None specified V74Gy ≤3% 
  V70Gy <25% 
  V67Gy <30% 
  V55.5Gy <50% 
  Minimum AP separation of 44Gy isodose and 
posterior rectal contour along midline >0 mm 
Femoral heads None specified D2cc <55Gy left and right 
 
  
17 
 
Figure 1: Phantom dosimetry results from the nine ProtecT centres 
 
 
 
 
The planned dose normalised for an error-free planning system and setup with negligible 
measurement error is plotted against actual dose by centre (1-9) measured using an 
anthropometric phantom. Doses at seven points around the prostate and irradiated volumes were 
predicted (using the centre system) and measured for both phases. 
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Table 2: Retrospective outlining assessment in the ProtecT trial 
 
Target volume (number 
assessed) 
 
Prostate 
(54)  
Seminal 
vesicles 
(54) 
Bladder 
(54) 
Rectum 
(54) 
Total 
(216) 
Satisfactory 40  35  53  40  167 
Acceptable variation 2 15 1  4 23 
Unacceptable variation 
Clinical significance: 
Unlikely 
 
 
9 
 
 
4  
 
 
0 
 
 
10 
 
 
23 
Possible 3 0 0 0 3 
Total 54 54 54 54 216 
 
 
 
 
 
Figure 2 Examples of protocol variations in  outlining in the ProtecT trial 
 
(a)      (b) 
 
CT slices from two  plans drawn by clinicians from two centers to illustrate protocol variations of 
potentially clinical significance: (a) CTVprostate included the seminal vesicles and missed some 
prostate tissue in a potentially significant clinical error, (b) seminal vesicles missed completely.  
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Figure 3. Compliance with rectal, bladder, femoral heads and PTV dose constraints in the 
ProtecT trial 
 
 
 
Two plans from one centre did not have dose data so were excluded from the total 54 plans. 
